Results 101 to 110 of about 3,904 (151)

[Analysis of induction therapy response in children with high-risk neuroblastoma]. [PDF]

open access: yesZhongguo Dang Dai Er Ke Za Zhi
Wang Y   +6 more
europepmc   +1 more source

Episodic numbness and weakness of limbs combined with shaking for three months [PDF]

open access: yes, 2013
CUI Li-ying   +4 more
core   +2 more sources

[Multiple myeloma with massive proliferation of signet ring cell like plasma cells: a case report]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Bai ZY   +6 more
europepmc   +1 more source

靶向治疗耐替莫唑胺胶质瘤耐药机制研究进展

open access: yesZhongguo shiyan zhenduanxue
胶质瘤,尤其是胶质母细胞瘤(GBM)作为最常见的原发性恶性脑肿瘤,其治疗现状仍面临着严峻的挑战[1-2]。目前,脑胶质瘤的年发病率约 5~8/10 万,大约相当于全部颅脑肿瘤的40%,且近年来发病率呈持续上升趋势[3]。尽管手术切除、放疗、化疗等综合治疗手段已经取得了一定的进展,但GBM的预后仍普遍较差,长期生存率极低[4]。
刘书绮, 滕登科, 谭诚, 刘俊志
doaj  

[Clinical data analysis of patients with middle ear cholesteatoma diagnosed with intracranial and extracranial complications as the first diagnosis]. [PDF]

open access: yesLin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
Li H   +6 more
europepmc   +1 more source

[Autologous hematopoietic stem cell transplantation with TBE conditioning in patients with primary central nervous system lymphoma]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Chen JL   +14 more
europepmc   +1 more source

[Research progress of large language models in tumor diagnosis: applications in textual reports and medical imaging]. [PDF]

open access: yesNan Fang Yi Ke Da Xue Xue Bao
Cheng H   +5 more
europepmc   +1 more source

梅花草提取物调节肠道菌群抑制原位脑胶质瘤模型的作用机制研究

open access: yesZhongguo shiyan zhenduanxue
目的 探讨脑胶质瘤发生过程中梅花草对原位荷瘤鼠肠道菌群的影响。方法 4周龄Balb/c雌性裸鼠颅内种植U87-MG或者RFP-U87-MG脑胶质瘤,前者用于肠道菌群检测(每组6只,分为2组),后者用于活体荧光成像评价脑胶质瘤的生长状态(每组3只,分为2组)。梅花草提取物经灌胃(25 mg/kg)隔天给药连续10次(植入后第6天至第24天),对照组为1×PBS。RFP-U87-MG模型鼠在第14天和第24天进行活体荧光成像观察肿瘤生长状态,同时进行裸鼠称量,并在第25天对裸鼠实施安乐死后,剥离脑组织和肿瘤,
王睿君   +3 more
doaj  

[Recurrent fever, persistent cytopenia]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Miao Y   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy